Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update – IT Business Net itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.
Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO trial of tebipenem HBr; Trial expected to begin with First Patient, First Visit in 4Q 2023 Conference call and webcast at 4:30pm ET.
By Colin Kellaher Spero Therapeutics has named Esther Rajavelu chief financial and business officer of the clinical-stage biopharmaceutical company. The.
Spero Therapeutics (SPRO) Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.